Dasatinib 20 Mg (Dasatinib)

Dasatinib 20 Mg is a prescription oral tablet formulated for the treatment of certain blood cancers. Each bottle contains 60 tablets, each delivering a precise 20 mg dose of dasatinib, a tyrosine‑kinase inhibitor. The product is manufactured by Natco Pharma Ltd., a company recognized for its commitment to quality generic oncology medications. Packaged in a sealed, tamper‑evident bottle, Dasatinib offers a convenient dosing schedule for patients requiring targeted therapy. Delivery typically occurs within 6 to 15 days after order placement, ensuring timely access to this life‑saving medication.

What is Dasatinib?

Dasatinib, known by the brand name Dasatinib, belongs to the class of kinase inhibitors that block abnormal signaling pathways driving cancer cell proliferation. It specifically targets the BCR‑ABL fusion protein and other Src family kinases implicated in chronic myeloid leukemia, acute lymphoblastic leukemia, and gastrointestinal stromal tumors. By interrupting these pathways, dasatinib halts disease progression and can induce remission in many patients. The 20 mg strength provides a balanced potency that minimizes severe toxicity while maintaining therapeutic efficacy. Clinicians often select this dosage for patients with stable organ function who require long‑term oral therapy.

Uses and Benefits

The primary indication for Dasatinib 20 Mg is the treatment of Philadelphia chromosome‑positive acute lymphoblastic leukemia and chronic myeloid leukemia, conditions where conventional chemotherapy often yields limited results. In addition, dasatinib is approved for gastrointestinal stromal tumors and certain cases of src‑driven solid tumors. Patients experience improved disease control, prolonged progression‑free survival, and reduced need for intravenous infusions. The oral formulation enhances quality of life, allowing individuals to maintain daily routines while receiving targeted therapy. Moreover, the fixed 20 mg dose simplifies regimen adherence, supporting consistent treatment outcomes.

How It Works

Dasatinib exerts its antineoplastic effect by binding to the ATP‑binding site of several tyrosine kinases, including BCR‑ABL, Src, and Lyn. This inhibition blocks downstream signaling cascades that drive uncontrolled cell division and survival in malignant cells. Consequently, the drug induces cell‑cycle arrest and promotes apoptosis in cancerous populations. Unlike broader‑spectrum chemotherapies, dasatinib’s selective targeting reduces collateral damage to healthy tissues, contributing to a more favorable safety profile. The 20 mg dosage delivers sufficient plasma concentrations to sustain pathway suppression throughout the dosing interval, ensuring continuous therapeutic pressure on the tumor.

Dosage Guidelines

The recommended adult dosage of Dasatinib 20 Mg consists of one tablet taken once daily, preferably at the same time each day to maintain steady plasma levels. Patients should swallow the tablet whole with water, avoiding crushing or chewing. Dosage adjustments are advised for individuals with moderate hepatic impairment or those taking strong CYP3A4 inhibitors, who may require a reduced dose of 10 mg daily. It is essential to follow the prescribing physician’s instructions and to undergo regular laboratory monitoring, including complete blood counts and liver function tests, to evaluate therapeutic response and detect adverse effects early.

Side Effects

Common adverse reactions associated with Dasatinib include gastrointestinal disturbances such as diarrhea, nausea, and abdominal pain, as well as skin rash and fatigue. More serious but less frequent events comprise interstitial lung disease, cardiac arrhythmias, and severe bleeding. Patients should be instructed to report persistent cough, shortness of breath, or unexplained weight loss immediately, as these may signal pulmonary complications. Routine ophthalmologic examinations are recommended because dasatinib can cause vision changes. Although most side effects are manageable with dose modifications or supportive care, clinicians must remain vigilant for rare but life‑threatening complications that require urgent medical intervention.

Warnings and Precautions

Prior to initiating Dasatinib therapy, health care providers must assess baseline cardiac function, as the drug can exacerbate pre‑existing arrhythmias. Patients with a history of severe hepatic disease should undergo dose reduction to avoid accumulation. Concomitant use of strong CYP3A4 inducers may diminish efficacy and should be avoided. Pregnant or breastfeeding individuals are advised against treatment due to potential fetal toxicity. Regular monitoring of blood counts, liver enzymes, and pulmonary status is mandatory throughout treatment. If severe side effects emerge, therapy should be paused and medical attention sought promptly to prevent irreversible organ damage.

Monitoring and Follow‑up

Regular laboratory monitoring is a cornerstone of safe dasatinib therapy. Physicians typically order complete blood counts every two weeks during the first two months, then monthly thereafter, to detect cytopenias early. Liver function tests should be checked at baseline and periodically to identify hepatotoxicity. Electrolyte disturbances and renal function may also require assessment, especially in patients with comorbidities. Additionally, an electrocardiogram is recommended at baseline and repeated if symptoms of arrhythmia develop. Adherence to this monitoring schedule enables timely intervention, reducing the risk of treatment‑related complications and supporting sustained therapeutic efficacy. Patients are encouraged to report any new or worsening symptoms promptly, as early detection of adverse events can significantly improve outcomes. Education about the signs of pulmonary hypertension, fluid retention, and severe skin reactions also empowers individuals to seek appropriate care.

Frequently Asked Questions

What is the recommended storage condition for Dasatinib tablets?

Dasatinib tablets should be stored at room temperature, away from moisture and heat. Keep the bottle tightly closed and out of reach of children. Do not refrigerate or freeze the medication. For detailed storage guidelines, refer to the FDA labeling FDA. Store the medication in its original container, protect it from direct sunlight, and avoid exposure to extreme temperatures. If the tablet appears discolored or damaged, discard it and obtain a new supply.

Can Dasatinib be taken with food?

Dasatinib should be taken on an empty stomach, at least one hour before or two hours after a meal, to ensure consistent absorption. Food can alter the drug’s bioavailability and potentially reduce its effectiveness. Patients are advised to follow these timing instructions precisely and to discuss any dietary concerns with their prescribing physician. If a dose is missed, the patient should not double up; instead, the next scheduled dose should be taken as usual.

What should I do if I experience severe side effects?

If severe side effects such as persistent cough, shortness of breath, irregular heartbeat, or significant bleeding occur, patients must seek immediate medical attention. These symptoms may indicate serious complications that require urgent evaluation. It is essential to contact a healthcare provider promptly or call emergency services. For more information on serious adverse events, consult the NIH’s drug safety database NIH.

Is Dasatinib safe during pregnancy?

Dasatinib is classified as a Category D medication, indicating that it may cause fetal harm when used during pregnancy. Women of reproductive potential should use effective contraception while taking the drug and for at least 30 days after discontinuation. If pregnancy occurs, the prescribing physician should be notified immediately to assess risks and determine appropriate next steps.

How long does it take to see therapeutic benefits?

Patients may begin to notice clinical improvements within several weeks after initiating Dasatinib therapy, though optimal response often requires several months of continuous treatment. Response is typically evaluated through laboratory tests and imaging studies performed at regular intervals. Individual variation depends on disease stage, genetic markers, and adherence to dosing. For detailed response criteria, refer to the MedlinePlus resource MedlinePlus.